Related references
Note: Only part of the references are listed.JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
Joerg Wenzel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Type I interferonopathies-an expanding disease spectrum of immunodysregulation
Min Ae Lee-Kirsch et al.
SEMINARS IN IMMUNOPATHOLOGY (2015)
Familial Chilblain Lupus Due to a Novel Mutation in the Exonuclease III Domain of 3' Repair Exonuclease 1 (TREX1)
Claudia Guenther et al.
JAMA DERMATOLOGY (2015)
Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy A Mimic of Childhood Granulomatosis With Polyangiitis
Justine Munoz et al.
JAMA DERMATOLOGY (2015)
SAMHD1 prevents autoimmunity by maintaining genome stability
Stefanie Kretschmer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations
Nadia Jeremiah et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Thorsten Hornung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Activated STING in a Vascular and Pulmonary Syndrome
Y. Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Regulation of type I interferon responses
Lionel B. Ivashkiv et al.
NATURE REVIEWS IMMUNOLOGY (2014)
STING and the innate immune response to nucleic acids in the cytosol
Dara L. Burdette et al.
NATURE IMMUNOLOGY (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Structural Analysis of the STING Adaptor Protein Reveals a Hydrophobic Dimer Interface and Mode of Cyclic di-GMP Binding
Songying Ouyang et al.
IMMUNITY (2012)
Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system
Chang Shu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Autosomal Dominant Inheritance of a Heterozygous Mutation in SAMHD1 Causing Familial Chilblain Lupus
Jane C. Ravenscroft et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2011)
Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response
Gillian I. Rice et al.
NATURE GENETICS (2009)
Trex1 prevents cell-intrinsic initiation of autoimmunity
Daniel B. Stetson et al.
CELL (2008)
Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease
Yun-Gui Yang et al.
CELL (2007)
A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus
Min Ae Lee-Kirsch et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome
Gillian Rice et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p
Min Ae Lee-Kirsch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Share Paper
